## Oskar Ragnarsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7278725/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Natural history and surgical outcome of Rathke's cleft cysts—A study from the Swedish Pituitary Registry. Clinical Endocrinology, 2022, 96, 54-61.	2.4	7
2	Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. European Journal of Endocrinology, 2022, 186, 329-339.	3.7	12
3	Increased Mortality Persists after Treatment of Cushing's Disease: A Matched Nationwide Cohort Study. Journal of the Endocrine Society, 2022, 6, bvac045.	0.2	4
4	Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer. Current Oncology, 2022, 29, 3494-3498.	2.2	3
5	α-Adrenoceptor blockers and phaeochromocytoma surgery: outdated combination?. British Journal of Surgery, 2022, 109, 887-888.	0.3	1
6	Ectopic ACTH- and/or CRH-Producing Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 598-608.	3.6	19
7	Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 814-825.	3.6	8
8	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1183-e1194.	3.6	48
9	Endocrinological diagnosis and replacement therapy for hypopituitarism. , 2021, , 135-146.		2
10	Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1750-1760.	3.6	15
11	Carpal tunnel syndrome in acromegaly: a nationwide study. European Journal of Endocrinology, 2021, 184, 209-216.	3.7	8
12	Pre―and postoperative <sup>68</sup> Gaâ€DOTATOC positron emission tomography for hormoneâ€secreting pituitary neuroendocrine tumours. Clinical Endocrinology, 2021, 94, 956-967.	2.4	7
13	Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial. ELife, 2021, 10, .	6.0	22
14	MCM7 as a marker of postsurgical progression in non-functioning pituitary adenomas. European Journal of Endocrinology, 2021, 184, 521-531.	3.7	6
15	MiR-122-5p: A Novel Biomarker of Glucocorticoid Action. Journal of the Endocrine Society, 2021, 5, A89-A89.	0.2	0
16	Increasing Incidence of Primary Aldosteronism in Western Sweden During 3 Decades – Yet An Underdiagnosed Disorder. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3603-e3610.	3.6	16
17	Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis. Pituitary, 2021, 24, 797-809.	2.9	9
18	The Prevalence of Tertiary Adrenal Insufficiency in Patients Receiving Topical Glucocorticoid Treatment for Oral Lichen Planus. Journal of the Endocrine Society, 2021, 5, A99-A99.	0.2	1

#	Article	IF	CITATIONS
19	Incidence of Benign and Malignant Tumors in Patients With Acromegaly Is Increased: A Nationwide Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3487-3496.	3.6	11
20	Adrenal Venous Sampling in Young Patients with Primary Aldosteronism. Extravagance or Irreplaceable?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2087-e2095.	3.6	17
21	Growth hormone deficiency in adults with hypopituitarism—What are the risks and can they be eliminated by therapy?. Journal of Internal Medicine, 2021, 290, 1180-1193.	6.0	14
22	Response to Letter to the Editor from Singhania et al: "Increasing incidence of primary aldosteronism in Western Sweden during three decades – Yet an underdiagnosed disorder― Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	0
23	High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. Clinical Endocrinology, 2020, 92, 21-28.	2.4	14
24	Lower <sup>68</sup> Gaâ€DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland—A proofâ€ofâ€concept study. Clinical Endocrinology, 2020, 92, 222-231.	2.4	11
25	Cushing's syndrome – Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101382.	4.7	12
26	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine, 2020, 70, 412-420.	2.3	6
27	MON-330 Cancer Incidence in 1,296 Patients with Acromegaly Is Not Increased: A Nationwide Population-Based Study. Journal of the Endocrine Society, 2020, 4, .	0.2	Ο
28	Primary Adrenal Leiomyosarcoma: Clinical, Radiological, and Histopathological Characteristics. Journal of the Endocrine Society, 2020, 4, bvaa055.	0.2	4
29	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	6.0	35
30	Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2616-2624.	3.6	42
31	Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency. Journal of the Endocrine Society, 2020, 4, bvaa160.	0.2	6
32	Reference intervals of salivary cortisol and cortisone and their diagnostic accuracy in Cushing's syndrome. European Journal of Endocrinology, 2020, 182, 569-582.	3.7	29
33	Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. European Journal of Endocrinology, 2020, 182, 523-531.	3.7	59
34	Extended Support Within a Person-Centered Practice After Surgery for Patients With Pituitary Tumors: Protocol for a Quasiexperimental Study. JMIR Research Protocols, 2020, 9, e17697.	1.0	6
35	MON-159 High Mortality Rate in Oral Glucocorticoid Users: A Case-Control Study. Journal of the Endocrine Society, 2020, 4, .	0.2	Ο
36	Adrenal venous sampling in patients with ACTH-independent hypercortisolism. Endocrine, 2019, 66, 338-348.	2.3	14

#	Article	IF	CITATIONS
37	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
38	Pituitary Metastases: A Nationwide Study on Current Characteristics With Special Reference to Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3379-3388.	3.6	22
39	Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2375-2384.	3.6	83
40	The incidence of endogenous Cushing's syndrome in the modern era. Clinical Endocrinology, 2019, 91, 263-270.	2.4	53
41	Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary, 2019, 22, 422-434.	2.9	95
42	The incidence of Cushing's disease: a nationwide Swedish study. Pituitary, 2019, 22, 179-186.	2.9	46
43	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2019, 180, X1-X3.	3.7	2
44	Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2019, 180, 329-338.	3.7	12
45	Radiotherapy as a tool for the treatment of Cushing's disease. European Journal of Endocrinology, 2019, 180, D9-D18.	3.7	18
46	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	3.7	53
47	MON-431 Clinical Presentation of Metastases to the Pituitary: A Swedish Nationwide Study. Journal of the Endocrine Society, 2019, 3, .	0.2	0
48	SUN-450 Comorbidities in 419 Patients with Cushing's Disease in Remission: A Swedish Nationwide Study. Journal of the Endocrine Society, 2019, 3, .	0.2	0
49	The pre- and postoperative illness trajectory in patients with pituitary tumours. Endocrine Connections, 2019, 8, 878-886.	1.9	6
50	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2018, 178, 459-469.	3.7	72
51	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp> . Clinical Endocrinology, 2018, 88, 787-798.	2.4	40
52	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	3.7	37
53	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
54	Diagnostic value of the water deprivation test in the polyuria-polydipsia syndrome. Hormones, 2018, 16, 414-422.	1.9	4

Oskar Ragnarsson

#	Article	IF	CITATIONS
55	Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 2018, 62, 737-739.	2.3	21
56	Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagnostic and Interventional Radiology, 2018, 24, 89-93.	1.5	36
57	Temporal relationship of sleep apnea and acromegaly: a nationwide study. Endocrine, 2018, 62, 456-463.	2.3	17
58	Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. European Journal of Endocrinology, 2018, 179, 229-237.	3.7	11
59	The urinary cortisol metabolome in patients with adrenal insufficiency: Dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy. Annales D'Endocrinologie, 2018, 79, 185.	1.4	Ο
60	Decreased prefrontal functional brain response during memory testing in women with Cushing's syndrome in remission. Psychoneuroendocrinology, 2017, 82, 117-125.	2.7	19
61	Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. European Journal of Endocrinology, 2017, 177, 251-256.	3.7	57
62	Pituitary dysfunction in granulomatosis with polyangiitis. Pituitary, 2017, 20, 594-601.	2.9	32
63	Reduced DNA methylation and psychopathology following endogenous hypercortisolism – a genome-wide study. Scientific Reports, 2017, 7, 44445.	3.3	33
64	Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. Endocrine-Related Cancer, 2017, 24, 227-235.	3.1	16
65	Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. European Journal of Endocrinology, 2017, 176, 715-725.	3.7	33
66	Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4264-4272.	3.6	38
67	The impact of adjustments to the diagnostic criteria for biochemical remission in surgically treated patients with acromegaly. Growth Hormone and IGF Research, 2017, 36, 16-21.	1.1	1
68	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	2.4	19
69	Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. Pituitary, 2017, 20, 218-224.	2.9	19
70	Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. European Journal of Endocrinology, 2016, 175, 55-61.	3.7	25
71	Urinary free cortisol and androgens in the population—Hormone interactions and the relationship with body composition and bone status. Steroids, 2016, 115, 154-159.	1.8	2
72	Mental Fatigue and Executive Dysfunction in Patients with Cushing's Syndrome in Remission. Behavioural Neurology, 2015, 2015, 1-6.	2.1	26

#	Article	IF	CITATIONS
73	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology, 2015, 173, R1-R14.	3.7	141
74	Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1689-1698.	3.6	142
75	Systematic review of surgery and outcomes in patients with primary aldosteronism. British Journal of Surgery, 2015, 102, 307-317.	0.3	102
76	The association between urinary cortisol excretion and cardiovascular risk factors, bone status and quality of life in the population. Steroids, 2015, 101, 71-77.	1.8	8
77	Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. European Journal of Endocrinology, 2015, 172, 1-10.	3.7	41
78	Common Genetic Variants in the Glucocorticoid Receptor and the 11β-Hydroxysteroid Dehydrogenase Type 1 Genes Influence Long-Term Cognitive Impairments in Patients With Cushing's Syndrome in Remission. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1803-E1807.	3.6	28
79	Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. European Journal of Endocrinology, 2014, 171, 369-377.	3.7	45
80	The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. European Journal of Endocrinology, 2014, 171, 571-579.	3.7	38
81	The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. European Journal of Endocrinology, 2014, 171, 519-526.	3.7	226
82	The Impact of Clucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1479-1485.	3.6	8
83	Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy. Frontiers of Hormone Research, 2014, 43, 33-44.	1.0	21
84	Effect of short-term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy. European Journal of Endocrinology, 2013, 168, 243-251.	3.7	11
85	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2013, 169, 211-215.	3.7	7
86	MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome: a structured short- and long-term management plan for patients in remission. European Journal of Endocrinology, 2013, 169, R139-R152.	3.7	45
87	Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer. BMJ Case Reports, 2013, 2013, bcr2013010395-bcr2013010395.	0.5	4
88	Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood. European Journal of Endocrinology, 2012, 166, 593-600.	3.7	5
89	Discontinuing Long-Term GH Replacement Therapy—A Randomized, Placebo-Controlled Crossover Trial in Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3185-3195.	3.6	37
90	Long-Term Cognitive Impairments and Attentional Deficits in Patients with Cushing's Disease and Cortisol-Producing Adrenal Adenoma in Remission. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1640-E1648.	3.6	86

#	Article	IF	CITATIONS
91	Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 473-481.	3.6	286
92	Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clinical Endocrinology, 2012, 76, 246-252.	2.4	26
93	Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. European Journal of Endocrinology, 2010, 162, 677-684.	3.7	27
94	Headache Before and After Endoscopic Transsphenoidal Pituitary Tumor Surgery: A Prospective Study. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.8	0
95	Limited value of the standard 8-hour water deprivation test in the diagnostic work-up of patients with suspected diabetes insipidus. Endocrine Abstracts, 0, , .	0.0	1
96	Increased glucocorticoid replacement doses are associated with excess mortality in patients with non-functioning pituitary adenoma. Endocrine Abstracts, 0, , .	0.0	1
97	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
98	Incidence of pituitary adenomas in Western Sweden in 20012011. Endocrine Abstracts, 0, , .	0.0	0
99	Patients with Addison's disease have increased frequency of the metabolic syndrome: a case–control study. Endocrine Abstracts, 0, , .	0.0	0
100	Sleep apnea in patients with acromegaly - prevalence, diagnosis and risk factors. Endocrine Abstracts, 0, , .	0.0	0
101	A Phase 3b, open-label, extension study to evaluate the long-term safety of once-daily, dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). Endocrine Abstracts, 0, , .	0.0	0
102	Mortality is increased in patients with Cushing's disease in long-term remission: A nation-wide study. Endocrine Abstracts, 0, , .	0.0	0
103	Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN. Endocrine Abstracts, 0, , .	0.0	0
104	Urinary steroid profile in patients with primary adrenal insufficiency under conventional glucocorticoid replacement: a case control study. Endocrine Abstracts, 0, , .	0.0	0
105	The urinary cortisol metabolome in patients with adrenal insufficiency: dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy. Endocrine Abstracts, 0, , .	0.0	0
106	Adrenal venous sampling in patients with ACTH-independent Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
107	Salivary cortisol and cortisone in Cushing diagnosis - reference ranges and clinical cut off limits. Endocrine Abstracts, 0, , .	0.0	0
108	The prevalence of oral glucocorticoid use in doses associated with risk of tertiary adrenal insufficiency. Endocrine Abstracts, 0, , .	0.0	1

#	Article	IF	CITATIONS
109	DNA Methylation and fMRI responses in patients with Cushing's syndrome in remission - suggestions of a functional link between hypercortisolism and neurocognitive dysfunction. Endocrine Abstracts, 0, , .	0.0	0
110	Prolonged diagnostic delay in acromegaly is associated with long-term morbidity and excess mortality: data from a nationwide study. Endocrine Abstracts, 0, , .	0.0	0
111	European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale. Endocrine Abstracts, 0, , .	0.0	0
112	Carpal tunnel syndrome is common in patients with undiagnosed acromegaly – a swedish nationwide study. Endocrine Abstracts, 0, , .	0.0	0
113	Etiology and extent of impaired quality of life, fatigue and affective, cognitive, and emotional dysfunction in patients with cushing's syndrome – The IQFACE-CS study. Endocrine Abstracts, 0, , .	0.0	0
114	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine Abstracts, 0, , .	0.0	1
115	High usage of drugs for neuropsychiatric morbidity in patients with Cushing´s disease before diagnosis and at 5–10 years follow-up – a nationwide study. Endocrine Abstracts, 0, , .	0.0	0
116	High Mortality Rate in Oral Glucocorticoid Users: A Population-Based Matched Cohort Study. Frontiers in Endocrinology, 0, 13, .	3.5	10